VIDEO: Interesting treatments in the pipeine for metastatic breast cancer

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

In terms of what's in the pipeline, I think we're all interested in how the FDA will react to the elecestrant data that we saw from San Antonio in 2021. This was a randomized phase three trial comparing elecestrant versus endocrine therapy, a provider choice, in patients who have endocrine refractory, ER positive, Her2 negative breast cancer. And so, you know, that certainly is one of a wave of lots of new endocrine agents that are in clinical development of many across all phases of clinical trials and include not only SERDS, oral SERDS but also protax and CER-ands and a whole range of abbreviations for these novel endocrine agents. And I think will hopefully drive, you know the next wave of improvements for ER positive, Her2 negative metastatic breast cancer. And then there's a lot of activity still around antibody drug conjugates, and in all different types of breast cancer whether that's an ER positive, triple negative or Her2 positive with new agents as well as potential new indications for old agents. So I'm definitely keeping an eye on the ADC space.